Evaluate for Investment Banking
Build stronger pharma and biotech deal strategies with trusted market intelligence
Evaluate helps investment banking teams assess pharma and biotech companies, assets and markets with trusted forecasts, valuation tools, pipeline intelligence and catalyst tracking.
Why investment banking teams use Evaluate
In pharma and biotech investment banking, strong client advice depends on understanding the market evidence behind the deal.
Banking teams need to assess where value sits, how durable the opportunity is, which assets or companies are strategically attractive, and what clinical, regulatory or competitive events could affect timing, valuation or market perception.
Evaluate brings together company, drug, forecast, pipeline and catalyst intelligence so teams can build stronger pitch materials, challenge assumptions, support valuation work and give clients more confident recommendations.
drugs across marketed and pipeline assets
biopharma companies across private and listed markets
event types covering clinical, regulatory, legal and commercial catalysts
Used by 98% of the top 50 pharma companies
Trusted intelligence across the pharma and biotech ecosystem
Built for investment teams, trusted across pharma and biotech.
- Forecasts to 2032 for forward-looking market sizing and investment evaluation
- Historic sales data back to 1996 for long-term performance context
- Coverage across private and listed biopharma companies, marketed products and pipeline assets
Built for key investment banking workflows
Get in touch
Whether you are preparing a client pitch, screening M&A targets, supporting an IPO, advising on licensing opportunities or pressure-testing valuation assumptions, Evaluate helps you build a clearer view of the market, the asset and the deal story.
M&A target screening and market mapping
Identify companies, assets or business units that could support acquisition, divestment or strategic review opportunities.
Use Evaluate to compare companies, review product portfolios, assess forecast sales, understand competitive threats and identify upcoming catalysts that could influence deal timing or valuation.
Useful when you need to:
- Build target lists around therapy areas, geographies or market segments
- Compare companies by portfolio, pipeline strength or forecast potential
- Support buy-side, sell-side or strategic advisory work
Client pitch and meeting preparation
Prepare stronger client conversations with market evidence, peer context and timely insight.
Use Evaluate to understand product performance, market trends, competitor activity, relevant catalysts and company positioning before a pitch, update meeting or strategic discussion.
Useful when you need to:
- Build sharper pitch materials
- Identify timely client conversation starters
- Support recommendations with market and product-level evidence
IPO and capital raising support
Build stronger market narratives for pharma and biotech companies preparing to raise capital or enter public markets.
Use Evaluate to assess market size, product potential, clinical milestones, competitive positioning, peer companies and long-term revenue opportunity.
Useful when you need to:
- Support IPO or financing preparation
- Size the commercial opportunity
- Strengthen the growth story behind a raise
Asset valuation and scenario planning
Assess the potential value of marketed and pipeline assets using pharma-specific forecasts and scenario analysis.
Use Evaluate’s NPV tools and forecast data to test assumptions around future sales, competitive launches, biosimilar risk, pricing, costs, tax changes and other variables that may affect asset value.
Useful when you need to:
- Pressure-test valuation assumptions
- Build or validate NPV models
- Compare upside and downside cases
Catalyst and deal timing analysis
Track the clinical, regulatory, legal and commercial events that could change market perception, valuation or transaction timing.
Use Evaluate Biomedtracker to monitor trial readouts, PDUFA dates, approvals, patent disputes, litigation, product launches, competitor milestones and M&A activity across products, companies and therapy areas.
Useful when you need to:
- Monitor live deal risks
- Prepare for market-moving events
- Understand what could shift valuation or timing
Licensing and partnership advisory
Assess asset attractiveness, market fit and commercial potential when advising on licensing, co-development or strategic partnership opportunities.
Use Evaluate to understand comparable assets, forecast opportunity, competitor dynamics, relevant pharma partners and the broader market context behind potential partnership decisions.
Useful when you need to:
- Evaluate licensing or co-development opportunities
- Compare assets within a therapy area
- Advise clients on strategic options
Comparable company and peer benchmarking
Benchmark companies, assets and portfolios against relevant peers.
Use Evaluate to compare forecast potential, marketed product exposure, pipeline strength, therapy area focus, development stage and upcoming catalysts across comparable companies.
Useful when you need to:
- Support valuation and benchmarking work
- Strengthen client materials with peer context
- Assess how a company or asset compares in the market
The data and tools behind the workflows
Evaluate gives investment banking teams a connected view of the companies, assets, forecasts, pipelines, events and market commentary behind pharma and biotech deal decisions.
Consensus forecasts and sales data
Size markets, assess historic and future sales potential, and benchmark assets across drugs, companies, indications and therapy areas.
Company and asset coverage
Analyze listed and private biopharma companies, marketed products, pipeline assets and company portfolios.
Pipeline intelligence
Review development stage, indication focus, clinical progress and competitor activity to understand future growth potential and risk.
NPV Analyzer
Model asset value using adjustable assumptions across future sales, pricing, competitive threats, risk and development scenarios.
Calendar of Events
Track clinical, regulatory, legal and commercial catalysts that could affect market perception, valuation or deal timing.
Peer Group Analyzer
Compare companies against relevant peers to support market mapping, target screening, benchmarking and client materials.
Report Builder
Create focused views of companies, drugs, therapy areas or development stages to support pitch preparation, market mapping and diligence workflows.
Venture financing and deal intelligence
Benchmark previous financing rounds, IPOs, licensing deals and comparable company activity to support transaction analysis and client recommendations.
News & Insights
Keep up to date with the market signals shaping pharma and biotech investment decisions through expert analysis, exclusive interviews and market commentary from Scrip, In Vivo, Pink Sheet and Medtech Insight, covering key deals, strategy shifts, leadership changes, regulatory developments and wider biopharma market trends.
Build stronger pharma and biotech deal strategies with Evaluate
See how Evaluate helps investment banking teams screen targets, assess markets, value assets, track catalysts and support client recommendations with trusted biopharma intelligence.
Frequently Asked Questions
How can Evaluate support M&A target screening?
Evaluate helps banking teams identify and assess pharma and biotech companies by product portfolio, pipeline strength, forecast potential, therapy area focus, market exposure and competitive position.
This supports target list creation, market mapping and early prioritization for buy-side, sell-side or strategic advisory work.
How does Evaluate support client pitch preparation?
Evaluate provides company, asset, forecast, pipeline, peer and catalyst intelligence that can be used to strengthen pitch materials and client conversations.
This helps teams bring more relevant market context, sharper deal angles and better evidence into meetings.
Can Evaluate support IPO and capital raising work?
Yes. Evaluate helps teams assess market size, product potential, competitive positioning, clinical milestones, peer companies and long-term revenue opportunity.
This can support IPO preparation, investor materials, financing narratives and growth story development.
How can Evaluate help with valuation and scenario planning?
Evaluate’s forecast data and NPV tools help teams test assumptions around future sales, pricing, launch timing, competitive threats, biosimilar risk, costs and development scenarios.
This can support NPV modelling, upside and downside cases, and more defensible client recommendations.
Can Evaluate help with licensing and partnership advisory?
Yes. Evaluate helps teams assess asset attractiveness, comparable products, forecast opportunity, competitor dynamics and potential strategic fit.
This supports licensing, co-development, partnership and broader strategic advisory conversations.
How does Evaluate help teams track deal timing and risk?
Evaluate tracks clinical, regulatory, legal and commercial catalysts including trial readouts, approvals, PDUFA dates, patent events, litigation, product launches and M&A activity.
This helps teams monitor live deal risks, identify timely client conversation starters and understand what could affect valuation or transaction timing.
